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Background: Limited empirical evidence exists for hepatitis C virus (HCV) treatment-as-
prevention. The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study 
assessed HCV treatment-as-prevention in four Australian prisons. 
Methods: SToP-C is a non-randomised trial, including a pre/post analysis within a prospective 
longitudinal cohort of people incarcerated in two maximum- (male) and two medium-security 
prisons (one male, one female). All prison inmates at least 18 years were eligible for enrolment. 
Participants were enrolled from late-2014 to 2019. Following HCV testing, participants were 
monitored for risk behaviors and HCV, among three sub-populations: 1) uninfected (HCV 
antibody negative); 2) previously infected (HCV antibody positive, HCV RNA negative); 3) 
infected (HCV antibody and HCV RNA positive). Uninfected and previously infected (at-risk) 
participants were followed every 3-6 months for HCV primary infection and re-infection, 
respectively. Infected participants were assessed for treatment, initially standard of care 
treatment (by prison health services), followed by direct-acting antiviral (DAA) treatment 
scale-up from mid-2017 (12 weeks sofosbuvir/velpatasvir, through SToP-C). Participants were 
followed until study closure in November 2019. The primary study outcome was HCV 
incidence compared between pre- and post-treatment scale-up periods among participants at 
risk of HCV primary infection or re-infection. The trial was registered with ClinicalTrials.gov 
(identifier: NCT02064049) 
Findings: Of 3,691 participants enrolled, 719 (19%) had detectable HCV RNA and 2,965 were 
at-risk of primary infection (n=2,240) or re-infection (n=725) at baseline. DAA treatment was 
initiated in 349/499 eligible participants during the treatment scale-up period. Among at-risk 
population with longitudinal follow-up (n=1,643; median age 33 years; 82% male), 31% 
reported injecting drug use in prison. HCV incidence declined by 48%, from 8.31 to 4.35/100 




0.52, 95%CI: 0.36, 0.78]. Incidence of primary infection declined from 6.64 to 2.85/100 person-
years (IRR: 0.43, 95%CI: 0.25, 0.74), while incidence of re-infection declined from 12.36 to 
7.27/100 person-years (IRR: 0.59, 95%CI: 0.35, 1.00). Among participants reporting injecting 
drug use in the current imprisonment, incidence of primary infection declined from 39.08 to 
14.03/100 person-years (IRR: 0.36, 95%CI: 0.16, 0.80), and incidence of re-infection declined 
from 15.26 to 9.34/100 person-years (IRR: 0.61, 95%CI: 0.34, 1.09). Adjusted analysis 
indicated a significant reduction in HCV risk between pre- and post-treatment scale-up periods 
(adjusted Hazard Ratio: 0.50, 95% CI: 0.33, 0.76). 
Interpretation: DAA treatment scale-up was associated with reduced HCV incidence in 
prison, indicative of HCV treatment-as-prevention. The findings support broad DAA treatment 
scale-up among incarcerated populations. 
 
Funding: The SToP-C study was funded by an Australian National Health and Medical 
Research Council (NHMRC) Partnership Project Grant (APP1092547), including support from 
Gilead Sciences. 
 





RESEARCH IN CONTEXT 
Evidence before this study 
We searched MEDLINE and Scopus for papers published up to 10 September 2020, using a 
combination of search terms, including ("hepatitis C" OR HCV) AND treatment* AND 
(prevent* OR incidence) AND ("direct acting antiviral*" OR DAA) AND (prison* OR jail* 
OR correction* OR convict*). We found no interventional studies investigating hepatitis C 
virus (HCV) treatment-as-prevention in prison settings. Some repeated surveys demonstrated 
decreased HCV prevalence following increased uptake of HCV treatment in prisons. However, 
these studies did not include systematic surveillance and did not evaluate risk status or HCV 
incidence. Some modelling studies have suggested that increasing HCV treatment uptake in 
prisons and improved harm reduction strategies could control HCV transmission and decrease 
HCV incidence. However, there is limited empirical evidence to support these findings in a 
real-world setting. 
 
Added value of this study 
To our knowledge, this is the first HCV treatment-as-prevention study in the prison setting, and 
the largest interventional HCV treatment-as-prevention study in any setting. This study 
provides empirical evidence of HCV treatment-as-prevention, with the HCV incidence almost 
halved (from 8.3 to 4.4/100 person-years) following rapid scale-up of sofosbuvir/velpatasvir 
treatment within four prisons, including several thousand participants in two maximum and two 
medium-security prisons. The magnitude of the HCV treatment-as-prevention effect was larger 
against primary HCV infection than HCV re-infection, and in participants who reported 






Implications of all the available evidence 
The World Health Organization has set a goal to eliminate HCV as a major global public health 
threat by 2030, including reducing the number of new HCV infections by 80%. In most 
countries, prisons are a priority setting for HCV elimination efforts, given the high prevalence 
and incidence in most prisons. The findings of the SToP-C study highlight both the feasibility 
and the positive impact of HCV direct-acting antiviral treatment scale-up in reducing the 
incidence of HCV infection in the prison setting. This demonstration of effective HCV 
treatment-as-prevention should encourage enhanced access to direct-acting antiviral treatment, 







Globally, an estimated 71 million people have chronic hepatitis C virus (HCV) infection.1 The 
advent of direct-acting antiviral (DAA) regimens have led a revolution in HCV therapy,2 with 
simple (once daily dosing oral regimens), well-tolerated, short-duration (8-12 weeks), pan-
genotypic treatment with cure rates >95%. The broad implementation of DAA therapy has 
considerable public health potential, with the World Health Organization setting ambitious 
HCV elimination impact targets, including an 90% reduction in HCV incidence, 80% of the 
infected population treated, and a 65% reduction in HCV mortality by 2030.3  
 
The capacity to achieve HCV elimination targets depends on many factors, but provision of 
DAA therapy to marginalized populations with HCV infection is crucial. People who inject 
drugs are incarcerated at high rates for drug-related crimes.4 Thus, in many countries, people 
who inject drugs and people who are incarcerated are priority populations, given their high 
burden of HCV infection, and their role in ongoing HCV transmissions.5,6 Delivery of effective 
HCV prevention and treatment interventions to these two populations is central to elimination 
efforts. Improving HCV prevention measures in the prisons is also important for controlling 
HCV in the community, given high transitioning between prison and community. 
 
Treatment-as-prevention, initially used in the context of HIV therapy,7 incorporates treatment 
as a tool for limiting spread of an infection in epidemics in a particular setting.8 Although 
mathematical modelling has demonstrated the potential for HCV treatment-as-prevention 
among people who inject drugs and in prison settings,5,6,9 very limited empirical data exists to 
confirm these modelling-based impact projections in a real-world setting. The demonstration 




efforts.7,10 Similarly, well-conducted, large-scale clinical trials are now required to evaluate 
HCV treatment-as-prevention.  
 
We hypothesised that rapid DAA-based treatment scale-up in prison would reduce HCV 
transmission, defined by the incidence of primary HCV infection and HCV re-infection. The 
Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) evaluated the impact of 





Study setting and design 
The SToP-C study was a non-randomised clinical trial evaluating HCV treatment-as prevention, 
including a pre/post analysis of HCV incidence within a longitudinal cohort of participants 
enrolled through four prisons in New South Wales, Australia. Two prisons (Goulburn, and 
Lithgow) predominantly house people in maximum-security prisons (male prisons), and two 
prisons predominantly house people in medium-security prisons, one male (Outer Metropolitan 
Multi-Purpose Correctional Centre; OMMPCC), and one female (Dillwynia) prison. These 
prisons had a combined cross-sectional population of 1,452 incarcerated individuals in 2016 
(Appendix p1).11 of whom approximately one third were unsentenced (i.e., on remand). All 
prisons offered harm reduction services, including opioid agonist therapy (OAT), access to the 
quaternary ammonium disinfectant, Fincol (Jasol, North Ryde, NSW, Australia) to cleanse 
injecting equipment, but not needle-syringe programs. Participant enrolment started in October 
2014 at Goulburn, in July 2015 at Lithgow, and in April 2016 at OMMPCC, and Dillwynia.  
 
The SToP-C study consisted of two major phases: a pre-DAA treatment scale-up phase or 
surveillance phase), and DAA treatment scale-up phase. In the initial phase of the study (pre-
DAA treatment scale-up) from October 2014 to mid-2017, HCV treatment was standard of care 
through a nurse-led model of care,12,13 including interferon-based treatment until March 2016 
when DAA treatment became available following the Australian Government subsidised 
listing,14 which included access for those in custody.13 Standard of care HCV treatment numbers 
remained relatively low throughout this phase. In the second phase of the study, rapid scale-up 
of DAA treatment started from mid-2017 (June 2017 in Goulburn and Lithgow; September 2017 
in Dillwynia; and October 2017 in OMMPCC), and ran until study closure in November 2019. 




SToP-C as a trial intervention), compared to interferon therapy as standard of care but with an 
expectation that DAAs would become the standard within the duration of the trial. We 
hypothesized low treatment uptake in the initial phase of the study, even with DAA as standard 
of care, given the limited capacity of prison health services. 
 
Study participants 
All prison inmates who were at least 18 years old were eligible for enrolment, irrespective of 
HCV infection status, HCV treatment history, risk behaviours, or sentence/remand status. 
Exclusion criteria were lack of adequate English to provide informed consent, and individuals 
with a security designation making clinic attendance for study visits logistically difficult. 
Participants who were transferred to a non-SToP-C prison, or released to freedom (i.e., returned 
to community) after enrolment, could re-enter the study if subsequently re-incarcerated into any 
SToP-C prison.  
 
For the DAA intervention, participants with detectable HCV RNA underwent standard clinical 
and laboratory assessments. Participants with all HCV genotypes and liver disease stages (F0 to 
F4/compensated cirrhosis) were eligible for treatment. Exclusion criteria for treatment included 
clinical evidence of hepatic decompensation, ongoing severe psychiatric disease, or pregnancy. 
Laboratory exclusion criteria included alanine aminotransferase (ALT) and alanine aspartate 
(AST) levels >10 times upper limit of normal or platelet count <50,000/microlitre. People with 
current injecting drug use were eligible for treatment. Full eligibility criteria are provided in the 
study protocol, available at: https://kirby.unsw.edu.au/project/stop-c. 
 




Following informed consent, participants were tested for HCV exposure and infection at 
enrolment (HCV antibody and RNA). Thus, from the enrolment visit, participants formed three 
sub-populations: 1) uninfected (HCV antibody negative); 2) previously infected (HCV antibody 
positive and HCV RNA negative); 3) infected (HCV antibody and HCV RNA positive). 
Uninfected and previously infected (i.e., HCV “at-risk”) participants were followed for HCV 
primary infection and re-infection, respectively. Infected participants underwent pre-treatment 
clinical and laboratory assessments, transient fibro-elastography (FibroScan®), and evaluation 
of potential drug-drug interactions. During the initial phase, infected participants were referred 
for HCV treatment through the prison health service. During the second phase, from mid-2017 
(rapid DAA treatment scale-up), participants eligible for HCV treatment were offered 
sofosbuvir/velpatasvir for 12 weeks, a pan-genotypic DAA regimen. Sofosbuvir/velpatasvir was 
administered orally once daily as a fixed-dose combination tablet (400 mg of sofosbuvir and 
100 mg of velpatasvir). Participants who became re-infected post-treatment were offered re-
treatment. All initial clinical assessments were conducted by specifically trained nurses, then 
the case was discussed with an infectious diseases specialist and treatment prescribed.13 
 
Across the five-year study period, scheduled study visits were undertaken at enrolment, and 
then every three to six months. At enrolment, a demographic, clinical, and risk behavioural 
interview was administered by the research nurses. Risk behaviour questions included: injecting 
and non-injecting drug use type and frequency, sharing injecting equipment, non-drug use 
related HCV risks (e.g. tattooing, fights), receiving OAT, and using disinfectant to cleanse 
injecting equipment. The risk behaviour interview was repeated at all follow-up visits. At each 
visit, participants were also assessed for HCV infection or re-infection by HCV antibody and/or 
RNA testing. The study was promoted through awareness campaigns for correction officers, 




following each visit for participation. The value of this remuneration was approved by the ethics 
committees as an undue incentive (versus compensation for time and inconvenience) The study 
enrolment continued from October 2014 through to September 2019, with final follow-up in 
November 2019. 
 
In the sub-population receiving treatment through SToP-C, additional study visits were 
undertaken at baseline (treatment initiation), week four of treatment, week 12 of treatment (end 
of treatment), and week 12 post-treatment. Assessments at these visits included symptom-
directed physical examinations, assessment of HCV RNA, and standard laboratory testing. 
Study medication was dispensed four-weekly (for the majority) or on a daily observed basis, 
based on a standardised risk assessment for likely non-adherence. Participants transferred to a 
non-SToP-C prison continued DAA treatment, but not SToP-C study follow-up. Participants 
released to freedom were provided with their remaining therapy and a referral to a community 
primary care practitioner for follow-up.  
 
Laboratory assessments 
All samples were tested for HCV antibody and RNA in a central laboratory. The samples were 
tested for HCV Antibody using ARCHITECT Anti-HCV (Abbott, Chicago, IL, USA) and 
Murex anti-HCV (DiaSorin, Saluggia, Italy), for HCV RNA using COBAS TaqMan (Roche, 
Basel, Switzerland; lower limit of detection 15 IU/ml), hepatitis B surface antigen using 
ARCHITECT HBsAg (Abbott, Chicago, IL, USA), and HIV antibody using ARCHITECT HIV 
Ag/Ab Combo (Abbott, Chicago, IL, USA). HCV genotype was determined using COBAS 
HCV GT (Roche, Basel, Switzerland). Among participants with a positive HCV RNA test post-




post-treatment samples was undertaken to determine if recurrent HCV viraemia was due to 
virological failure (homologous strains) or re-infection (heterologous strains).  
 
Study definitions 
Incident HCV primary infection was defined as a positive HCV antibody test among participants 
with a negative HCV antibody at the previous visit. Incident HCV re-infection was defined as a 
positive HCV RNA test among participants with a negative HCV RNA at the previous visit. 
Among participants receiving HCV treatment in the study, post-treatment re-infection was 
defined as a recurrent positive HCV RNA test after the end of treatment with an HCV strain that 
was confirmed as heterologous from the primary infecting strain. 
 
Eligible for treatment was defined as participants with detected HCV RNA, no exclusion criteria 
for treatment, and at least one follow-up assessment after enrolment. 
 
Among participants who received HCV treatment, an end-of-treatment response (ETR) was 
defined as non-quantifiable HCV RNA at end of treatment. HCV treatment outcome was 
classified as sustained virological response (SVR12, defined as non-quantifiable HCV RNA at 
or after 12 weeks following the end of treatment); virological failure (defined as quantifiable 
HCV RNA at 12 weeks after the end of treatment with re-infection excluded on sequencing); or 
non-virological failure (including re-infection, death, premature treatment discontinuation, or 
loss to follow up).  
 
The date of incident HCV infection was estimated based on a hierarchical algorithm using 




a. Participants with no HCV treatment following the previous visit: mid-point between last 
HCV negative and first HCV positive test (HCV antibody or HCV RNA). 
b. Participants who received HCV treatment through SToP-C: mid-point between ETR and 
first HCV RNA positive test. 
c. Participants who received HCV treatment outside of SToP-C (prison health service or 
community) and achieved SVR12: mid-point between documented SVR12 and first 
HCV RNA positive test. 
 
Liver fibrosis stage was assessed by liver stiffness measurement (transient fibro-elastography). 
Significant liver fibrosis and cirrhosis were defined as liver stiffness >7.1 kPa and >12.5 kPa, 
respectively.15 Compensated liver disease was defined by: an international normalized ratio 
(INR) <1.8, a serum albumin >30 gr/L, and a total serum bilirubin <35 micromol/L. 
 
Study outcomes 
The primary outcome was HCV incidence rate ratio, comparing before and after DAA treatment 
scale-up periods. Although DAA treatment scale-up commenced in mid-2017, it was staggered 
across the four prisons and high treatment coverage was not achieved until the end of 2017. 
Thus, the “after” DAA treatment scale-up period was designated as January 2018 onward. 
Changes in HCV incidence, including primary infection and re-infection were reported. The 
secondary study outcome was HCV treatment outcome. 
 
Sample size calculation 
The study sample size was calculated for 80% and 90% statistical power in different scenarios, 
assuming various levels of HCV incidence before treatment scale-up and expected incidence 




10/100 person-years, the study needed 1,500, 310, and 106 person-years follow-up to have 90% 
power to detect 25%, 50%, and 75% incidence reduction, respectively. 
 
Statistical analysis 
The incidence of HCV infection (primary infection, re-infection and combined) and 
corresponding 95% confidence intervals (CI) was calculated as rates per 100 person-years using 
Poisson distribution, with follow-up censored at estimated date of incident HCV infection, last 
follow-up visit prior to prison transfer/release to freedom (where no return documented), or last 
study follow-up visit.  
 
HCV incidence rates were calculated for periods before DAA treatment scale-up (2014 to 2017) 
and after DAA treatment scale-up (2018 to 2019). The rates between before and after treatment 
scale-up periods were compared by calculating the incidence rate ratio (IRR) and corresponding 
95%CI, and by conducting a significance test (Mantel–Haenszel). HCV incidence rates were 
also calculated by six-monthly intervals across the whole study period. Given slower 
recruitment in the early stages of the study, the first interval was considered October 2014 to 
June 2016. Interrupted time series regression analysis,16 was then used to evaluate change in 
trend in HCV incidence between periods before and after DAA treatment scale-up. The model 
was adjusted for calendar time (six-monthly interval) and HCV prevalence among new prison 
entrants, as a surrogate of the HCV reservoir transferring from community to prison over time. 
Prevalence of HCV infection among participants who were enrolled to the study within six 
months of entering the prison was used for this adjustment. 
 
In stratified analysis, HCV incidence rates were compared between before and after treatment 




enrolment: i) participants who had never injected; ii) those who had a history of injecting but 
not in current imprisonment; iii) those who injected in current imprisonment.  
 
The risk of HCV infection between before and after treatment scale-up periods was also assessed 
using unadjusted and adjusted Cox proportional hazard regression analyses, with a priori 
covariates including: gender, age, Australian Indigenous ethnicity, duration of stay in prison at 
enrolment, previous imprisonment, injecting drug use status at each visit, and prison site. Given 
that prison sites were gender specific (three men-only and one women-only prisons), gender 
was not included in the adjusted model due to collinearity with prison site. Injecting drug use 
status was included as a time-varying variable in the models. Other potential covariates (e.g., 
tattooing, having sex, and being in a fight in prison) were not included in the model, to maintain 
the focus of the analysis on major well-known HCV risk factors, particularly injecting drug use. 
 
Given earlier commencement of participant enrolment in two maximum-security prison sites, a 
sensitivity analysis was performed restricting the analysis to participants from these two prisons. 
People in prison are highly transient, with many participants exiting the prison and re-entering 
during follow-up, in some of whom the estimated date of HCV incident infection fell during the 
time they were out of prison. Thus, another sensitivity analysis was performed excluding 
participants who were out of prison at their estimated date of HCV incident infection.  
 
Statistical significances were assessed at P<0.05 (two-sided P values). Data analysis was 






All participants provided written informed consent before study procedures. The study protocol 
was approved by New South Wales Justice Health and Forensic Mental Health Network Human 
Research Ethics Committee (HREC/14/JH/7), Aboriginal Health and Medical Research Council 
Human Research Ethics Committee (1047/14 and 1253/17) and New South Wales Corrective 
Services Ethics Committee. The study was conducted according to the Declaration of Helsinki 
and International Conference on Harmonization Good Clinical Practice (ICH/GCP) guidelines, 
and registered with clinicaltrials.gov (NCT02064049).  
 
Role of the funding source 
The study was funded jointly by the Australian National Health and Medical Research Council 
(NHMRC) and Gilead Sciences through a NMHRC Partnership Project grant. Gilead Sciences 
provided study medication. The funders had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The sponsor (The Kirby Institute, UNSW Sydney) 
collected the data, managed study samples, and monitored study conduct. The authors 
independently designed the study, supervised study conduct, had access to all data, performed the 
statistical analysis, drafted the manuscript, and had final responsibility for the decision to submit 






A total of 3,691 participants were enrolled (30 October 2014 to 30 September 2019), 
representing a coverage of 53-89% of all people incarcerated in the four SToP-C prisons up to 
September 2019. Most participants were male (82%; n=3010/3691) with a median age of 33 
years. Median duration of current imprisonment was nine months [inter-quartile range (IQR): 
3, 29 months], while 28% (n=1029/3691) were on remand. More than half of participants (52%; 
n=1926/3691) reported a history of injecting drug use, while 31% (n=1134/3691) reported 
injecting drugs during current imprisonment, and 22% (n=797/3691) reported injecting in the 
past month in prison. Among participants who reported injecting drugs during the current 
imprisonment, 28% (n=315/1134) were currently receiving OAT at enrolment. Among those 
reporting injecting in the past month, 91% (n=722/797) reported sharing injecting equipment 
while in prison (Table 1).  
 
At enrolment, among 3,691 participants, 2,240 (61%) had a negative HCV antibody (at-risk of 
primary HCV infection), 725 (20%) had a positive HCV antibody and negative HCV RNA (at-
risk of HCV re-infection), and 719 (19%) had a positive HCV RNA (HCV infection; Figure 1). 
The prevalence of HCV infection at enrolment decreased from 29% among those enrolled 
before June 2016 to 10% among those enrolled after July 2019 (Figure 2A). 
 
A total of 1,873 participants had at least one follow-up visit after enrolment. Baseline 
characteristics were comparable between participants with, and without, follow-up. As the only 
exception, those with follow-up had a longer time in prison at enrolment (median: 14 versus 6 





Clinical assessments and DAA treatment in participants with HCV infection 
Among 719 participants HCV RNA positive at baseline, 315 (44%) had HCV genotype 1 
infection, 308 (43%) genotype 3, and 26 (4%) other or mixed genotypes. In 70 participants, 
genotype results were not available (in n=67 due to low viral load). Twenty participants (3%) 
had severe liver fibrosis (F3) and 14 (2%) had cirrhosis (F4). No participant had HIV, while six 
(1%) had chronic hepatitis B. 
 
A total of 499 HCV RNA positive participants had follow-up assessments after baseline, 
including 416 participants HCV RNA positive at baseline and 83 participants with incident 
HCV and no spontaneous clearance during follow-up. In the initial phase (October 2014 to mid-
2017, pre-DAA treatment scale-up), 39 participants received HCV treatment though prison 
health service or in community during the time they returned to community (n=3 interferon-
based therapy). In the second phase (mid-2017 to September 2019, post-DAA treatment scale-
up), 349 participants received DAA treatment, among whom 324 participants received 
treatment through SToP-C and 25 participants through prison health service or in community 
(Figure 3). 
 
Among 324 participants receiving treatment through SToP-C, 211 (65%) stayed in prison until 
end of treatment (completed treatment), while 113 participants (35%) exited before treatment 
completion due to prison transfer (n=63), release to freedom (n=48), or consent withdrawal 
(n=2). Among 143 participants who completed treatment and had an SVR12 assessment only 








A total of 1,643 participants were at-risk of HCV during follow-up and contributed to the HCV 
incidence analysis (Figure 1). The at-risk population was 82% male (n=1350) with a median 
age of 33 years, and 31% (n=487) reported injecting drugs in the current imprisonment at 
enrolment ( Appendix p2-3). Median follow-up was 10 months (IQR: 5, 18) in the overall 
analysis population, including 10 months (IQR: 5, 19) among participants sentenced and 8 
months (IQR: 5, 14) among those on remand. Over 1,818 person-years of follow-up, 111 
incident HCV infections were detected, including 57 primary infections and 54 re-infections. 
Five participants experienced two incident infection episodes (the second episode occurred 
following spontaneous or treatment-induce clearance of the first incident infection). The 
incidence rates of HCV infection, primary infection, and re-infection during the entire study 
follow-up were: 6.11/100 person-years (95% CI: 5.07, 7.35), 4.60/100 person-years (95%CI: 
3.56, 5.96), and 9.34/100 person-years (95% CI: 7.15, 12.19), respectively. The HCV incidence 
was 5.48/100 person-years (95%CI: 4.40, 6.83) among sentenced participants and 9.07/100 
person-years (95%CI: 6.34, 12.98) among those on remand. 
 
HCV incidence increased prior to treatment scale-up, from 6.73/100 person-years (95% CI: 
3.91, 11.60) to 10.93/100 person-years (95% CI: 7.54, 15.82) through December 2017. 
Following HCV treatment scale-up, the incidence declined to 5.13/100 person-years (95% CI: 
3.10, 8.52) in January-June 2018, and was between 2.20 and 5.60/100 person-years for the 
remainder of the study (Figure 4).  
 
The analysis comparing the incidence rate before treatment scale-up (2014-17) with after 
treatment scale-up (2018-19), indicated a 48% reduction from 8.31 to 4.35/100 person-years 




infection (from 6.64 to 2.85/100 person-years; IRR: 0.43, 95%CI: 0.25, 0.74, P<0.01) and 41% 
for re-infection (from 12.36 to 7.27/100 person-years; IRR: 0.59, 95%CI: 0.35, 1.00, P=0.05; 
Table 2).  
 
The prevalence of HCV infection among participants enrolled within six months of entering the 
prison decreased from 27% (n=36/135) among those enrolled before June 2016, to 12% 
(n=15/125) among those enrolled after July 2019 (Figure 2B), suggesting reductions in HCV 
reservoir transferring from community to prison during the study period. The interrupted time 
series regression analysis adjusted for calendar time (underlying trend) and HCV prevalence 
among new prison entrants, the change in trend of HCV incidence following DAA treatment 
scale-up was still significant (adjusted IRR: 0.43, 95%CI: 0.21, 0.88, P=0.02). This analysis 
also indicated reductions in HCV primary infection (adjusted IRR: 0.41, 95%CI: 0.15, 1.11, 
P=0.08), and HCV re-infection (adjusted IRR: 0.44, 95%CI: 0.16, 1.20, P=0.11), although 
neither was statistically significant. 
 
In the stratified analysis by injecting drug use status at enrolment, participants who reported a 
history of injecting but not in current imprisonment, had a 60% reduction in HCV incidence 
from 10.30 to 4.10/100 person-years (IRR: 0.40, 95%CI: 0.16, 0.98, P=0.04). Among 
participants who reported injecting in current imprisonment, HCV incidence reduction was 
53%, from 21.74 to 10.25/100 person-years (IRR: 0.47, 95%CI: 0.30, 0.75, P<0.01). HCV 
incidence among participants who reported never injecting drugs was low throughout the study 
(Table 2). 
 
The Cox proportional hazard regression analysis indicated a 50% reduction in the risk of HCV 




Indigenous Australian ethnicity, duration of stay in the prison, previous imprisonment, injecting 
drug use status, and prison site [adjusted Hazard Ratio (HR): 0.50 (95% CI: 0.33, 0.76, P<0.01); 
Table 3]. Independent of study period, risk of HCV infection was lower in older participants 
(adjusted HR for each year increase in age: 0.92, 95% CI: 0.89, 0.95, P<0.01), and higher among 
participants with previous imprisonments (adjusted HR: 2.27, 95% CI: 1.21, 4.26, P=0.01). 
Compared to participants reporting no injecting in current imprisonment, risk of HCV infection 
was three-time higher among those who injected longer than six months ago (adjusted HR: 
3.32, 95% CI: 1.04, 10.59, P=0.04), and six times higher among those who injected during the 
previous six months (adjusted HR: 6.14, 95% CI: 3.16, 11.92, P<0.01; Table 3).  
 
In a sensitivity analysis, restricting the study population to participants enrolled from two 
maximum-security prisons, results were similar ( Appendix p4,6). In another sensitivity 
analysis, participants whose estimated date of HCV incident infection fell in the time when they 





The SToP-C study provides empirical evidence for HCV treatment-as-prevention in the prison 
setting, with a significant reduction in HCV incidence following rapid scale-up of DAA therapy 
in four prisons in New South Wales, Australia. The findings support enhanced HCV treatment 
access and coverage among incarcerated people, including unrestricted access to DAA 
treatment and rapid treatment scale-up, to improve individual health outcomes and boost HCV 
elimination efforts within the prison and broader community settings. 
 
The observed incidence of HCV infection prior to DAA treatment scale-up was 8.3/100 person-
years, consistent with a previous study from New South Wales prisons which only included 
people who inject drugs and documented an HCV incidence of 11.4/100 person-years.17 Of 
note, HIV prevalence in Australian prisons is very low,18 (zero in our study), contrasting with 
many other prison settings.19  
 
A reduction in HCV incidence from 8.3 to 4.4/100 person-years following DAA treatment 
scale-up was demonstrated in the SToP-C study. Although a decrease in HCV prevalence 
among new prison entrants was also observed during the study period, the analysis adjusted for 
HCV prevalence, still showed a significant reduction in HCV incidence, providing strong 
evidence of HCV treatment-as-prevention, particularly in a setting where harm reduction 
measures may not be optimal. 
 
As expected, the HCV incidence was higher among participants with a prior history of injecting 
drug use, and was highest among those reporting injecting within the past month. Further, the 
greatest reduction in HCV incidence following DAA treatment scale-up was among the people 




population with recent injecting drug use. HCV incidence was consistently very low among the 
45% of the SToP-C study population without a history of injecting drug use at enrolment. This 
finding also suggests good validity of the self-reported HCV risk behaviour, and a low risk of 
HCV transmission through non-injecting means.  
 
There are several reasons for the non-significant impact of DAA treatment scale-up on HCV 
re-infection. First, statistical power was more limited than for the overall HCV incidence 
evaluation or for primary infection. Second, detection of HCV re-infection is partly related to 
frequency of HCV RNA testing.20,21 Primary infection is determined on the basis of HCV 
antibody seroconversion which is sustained. In contrast, re-infection cases can undergo 
spontaneous clearance and avoid detection, particularly in a setting of six-monthly HCV RNA 
testing.22 Finally, HCV treatment of high-risk individuals initially expands the susceptible 
population for HCV re-infection and thereby increases the risk level in this population. 
Irrespective of these potential explanations, further strategies are required to reduce HCV re-
infection in the prison setting, e.g., enhanced harm reduction interventions. 
 
During the first two years of access to prison health service-led DAA treatment (2016-17), only 
45 participants received treatment, whereas in the first six months after scale-up via SToP-C, 
142 participants received treatment, highlighting the feasibility of rapid scale-up. The rapid 
transition from diagnosis to treatment initiation is likely to boost treatment-as-prevention effect 
by reducing loss to follow-up and limiting the chance of ongoing transmissions. In the SToP-C 
study, the care cascade was used with venepuncture sampling and HCV testing in a central 
laboratory, necessitating several weeks delay in treatment initiation. By contrast, point-of-care 
HCV testing in prison has been shown to result in a significantly shorter time to treatment and 





Only a minority of the SToP-C participants (28%) were receiving OAT. A previous analysis of 
risk behaviours in a prospective cohort of people in Australian prisons who inject drugs, 
revealed increased risk behaviour following incarceration, with increased rates of sharing 
injecting equipment and increased use of opioids, including heroin and diverted methadone or 
buprenorphine.25 Mathematical modelling of HCV transmissions in the New South Wales 
prisons has demonstrated that DAA treatment scale-up to 40% of all people in prisons with 
HCV infection provided an effect size on incidence reduction comparable to that reported in 
the SToP-C study.5 Further, the modelling revealed that the combination of DAA treatment 
scale-up with enhanced access to OAT enabled greater HCV incidence reduction. Accordingly, 
expansion of OAT, including access to depot-buprenorphine preparations, in the prison setting 
should further reduce HCV risk behaviour. Although there are clear barriers to 
implementation,26 consideration needs to be given to evaluation of prison-based needle and 
syringe programs to match broad Australian community-based access. Continued HCV 
elimination efforts, particularly among community-based people who inject drugs, should also 
reduce HCV prevalence among people entering prison as was observed over time amongst those 
newly incarcerated who enrolled in the SToP-C study. 
 
Interferon-based treatment, was previously a major barrier against treatment uptake, given the 
significant side effects and long treatment duration. By contrast, DAA treatment has shifted the 
paradigm of HCV therapy with once daily oral dosing, minimal side effects, short duration, and 
very high efficacy. However, HCV treatment programs in prison settings worldwide have been 
relatively limited, often with small numbers of HCV infected individuals being treated.27,28 In 
Australia, specific arrangements were put in place to ensure prison-based access to the DAA 




correctional centres. While prison-based DAA treatment initiations constituted approximately 
6% of the national DAA treatment uptake in 2016,29 this figure increased to 31% in 2019,30 
crucial for national elimination efforts. DAA treatment scale-up in prison is also important for 
elimination efforts outside prison, given high transitioning between prison and community. We 
could not assess the impact of HCV treatment scale-up in prison on HCV transmission in the 
community given it was out of the scope of this study. Incarceration, however, if often a missed 
opportunity to provide HCV care to a highly marginalised population.31 An HCV testing and 
treatment program in Italian prisons reported that 81% of people diagnosed with HCV through 
screening in prison never received HCV care before incarceration.32 Surveillance of DAA 
treatment uptake in prison settings, therefore, is a key element of national elimination efforts. 
 
Once the SToP-C DAA treatment scale-up commenced, the uptake of DAA therapy among 
those with HCV was encouraging, with most individuals who were available for post-screening 
follow-up initiating therapy. The reasons for non-initiation of treatment were primarily related 
to the dynamic population of people in prison, including frequent transfers to other prisons and 
release to freedom. High DAA uptake was seen, despite earlier qualitative research from the 
SToP-C prior to DAA scale-up identifying concerns around HCV re-infection as a potential 
barrier to treatment initiation.33 Further studies are required to evaluate interventions to 
maintain the continuum of care for people diagnosed with HCV in prison, but transitioning, 
including initiatives for referral to community services for those released to freedom or to other 
prison health services for those transferred. 
 
The limitations of the SToP-C study firstly include a before and after evaluation design, rather 
than a larger cluster randomised controlled trial conducted across the 40 New South Wales 




Secondly, although enrolment coverage (i.e., the proportion of all those incarcerated in the four 
study prisons who were enrolled in the SToP-C study) reached over 80%, risk status and 
transmissions through people not enrolled in the study were not able to be measured. Third, the 
rate of transitioning of enrolled individuals between prisons, and of release to freedom was 
higher than anticipated, even among those incarcerated in maximum-security prisons. It is 
apparent that the often-used term “a captive population” to describe incarcerated people in the 
context of HCV elimination efforts is inappropriate both in terms of stigma and epidemiological 
reality. Less than half of participants had no follow-up visit, and among those with follow-up 
only 41% had follow-up extending beyond 12 months, demonstrating the highly dynamic nature 
of the population. However, background and behavioural characteristics of participants with 
and without follow-up were comparable, suggesting minimal chance of selection bias. Finally, 
although the study included one female prison, this centre had the lowest relative enrolment 
and person-years follow-up, making a stratified analysis by gender problematic. 
 
In conclusion, the SToP-C study has demonstrated an HCV treatment-as-prevention effect 
associated with DAA treatment scale-up in the prison setting. The findings support enhanced 
DAA therapy delivery for incarcerated populations, while suggest further consideration of HCV 
treatment-as-prevention strategies among the broader population at risk of HCV infection. The 
combination of rapid DAA scale-up with efficient HCV diagnosis, and enhanced primary HCV 
prevention strategies are likely to provide even greater impacts on HCV transmission given the 
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Table 1: Background and behavioural characteristics of SToP-C study participants at enrolment, overall 
and by year of enrolment 
  Total  
(n=3691) 











Prison site, n (%) 
      
  Goulburn 1,162 (31) 304 (81) 188 (27) 270 (30) 268 (27) 132 (19) 
  Lithgow 957 (26) 72 (19) 241 (34) 289 (32) 218 (22) 137 (20) 
  OMMPCC 891 (24) 0 161 (23) 210 (23) 308 (31) 212 (30) 
  Dillwynia 681 (18) 0 113 (16) 132 (15) 215 (21) 221 (31) 
Gender, n (%) 
      
  Female 679 (18) 0 113 (16) 132 (15) 215 (21) 219 (31) 
  Male 3010 (82) 376 (100) 590 (84) 769 (85) 794 (79) 481 (69) 
  Transgender 2 (<1) 0 0 0 0 2 (<1) 
Age (year), median (IQR) 33 (26, 41) 34 (26, 44) 34 (27, 41) 32 (26, 39) 33 (27, 40) 32 (26, 40) 
Aboriginal and or Torres Strait Islander, n (%) 
      
  No 2563 (69) 275 (73) 477 (68) 631 (70) 728 (72) 452 (64) 
  Yes 1005 (27) 95 (25) 174 (25) 236 (26) 279 (28) 221 (31) 
  Not available 123 (3) 6 (2) 52 (7) 34 (4) 2 (<1) 29 (4) 
Country of birth, n (%) 
      
  Australia 2905 (79) 309 (82) 530 (75) 703 (78) 802 (79) 561 (80) 
  Other countries 668 (18) 62 (16) 123 (18) 164 (18) 206 (20) 113 (16) 
  Not available 118 (3) 5 (1) 50 (7) 34 (4) 1 (<1) 28 (4) 
Formal education level, n (%) 
      
  No formal education or completed primary school 1238 (34) 127 (34) 244 (35) 335 (37) 285 (28) 247 (35) 
  Completed high school 1709 (46) 162 (43) 312 (44) 430 (48) 517 (51) 288 (41) 
  Tertiary education 613 (17) 80 (21) 97 (14) 98 (11) 203 (20) 135 (19) 
  Not available 131 (4) 7 (2) 50 (7) 38 (4) 4 (<1) 32 (5) 
Duration of stay in current prison (month), median (IQR) 9 (3, 29) 29 (10, 58) 13 (5, 36) 9 (3, 29) 7 (2, 23) 5 (2, 17) 
Previous imprisonment, n (%) 
      
  No 967 (26) 112 (30) 171 (24) 224 (25) 291 (29) 169 (26) 
  Yes 2607 (71) 259 (69) 482 (69) 643 (71) 718 (71) 505 (71) 
  Not available 117 (3) 5 (1) 50 (7) 34 (4) 0 28 (4) 
Tattoo or piercing in the prison (current imprisonment)       
  No 3152 (85) 343 (91) 567 (81) 758 (84) 879 (87) 605 (86) 
  Yes 419 (11) 30 (8) 77 (11) 103 (11) 130 (13) 79 (11) 




  Total  
(n=3691) 











Injecting drug use status, n (%) 
      
  Never injected 1654 (45) 170 (45) 271 (39) 395 (44) 496 (49) 322 (46) 
  Had history of injecting, but not in current imprisonment 792 (21) 63 (17) 126 (18) 206 (23) 229 (23) 168 (24) 
  Injected longer than 6 months ago (current imprisonment) 139 (4) 39 (10) 37 (5) 22 (2) 19 (2) 22 (3) 
  Injected in the previous 2-6 months (current imprisonment) 198 (5) 24 (6) 48 (7) 51 (6) 48 (5) 27 (4) 
  Injected in the previous month (current imprisonment) 797 (22) 76 (20) 176 (25) 191 (21) 217 (22) 137 (20) 
  Not available 111 (3) 4 (1) 45 (6) 36 (4) 0 26 (4) 
Opioid agonist therapy*, n (%) 
      
  Never 591 (52) 46 (33) 114 (43) 143 (53) 177 (62) 111 (60) 
  Yes, previously 237 (21) 34 (24) 80 (30) 81 (30) 72 (25) 48 (26) 
  Yes, currently 315 (28) 59 (42) 71 (27) 45 (17) 35 (12) 27 (15) 
Frequency of injecting†, n (%) 
      
  Less frequently than once a week 189 (24) 23 (30) 46 (26) 50 (26) 44 (20) 26 (19) 
  1 to 6 days per week, not daily 209 (26) 17 (22) 54 (31) 43 (23) 57 (26) 38 (28) 
  Once a day or more  389 (49) 36 (47) 72 (41) 92 (48) 116 (53) 73 (53) 
  Not available 10 (1) 0 4 (2) 6 (3) 0 0 
Re-used a needle or syringe after someone else  
had used it†, n (%) 
      
  No 76 (10) 12 (16) 13 (7) 16 (8) 22 (10) 13 (10) 
  Yes 709 (89) 63 (83) 159 (90) 168 (88) 195 (90) 124 (91) 
  Not available 12 (2) 1 (1) 4 (2) 7 (4) 0 0 
Re-used any injecting equipment after someone else  
had used it†, n (%) 
      
  No 63 (8) 9 (12) 13 (7) 14 (7) 19 (9) 8 (6) 
  Yes 722 (91) 66 (87) 159 (90) 170 (89) 198 (91) 129 (94) 
  Not available 12 (2) 1 (1) 4 (2) 7 (4) 0 0 
* Among participants who injected anytime in current imprisonment (n=1134) 




Table 2: Comparison of the incidence rates of HCV infection between before and after 2017, in overall 





Incidence rate (95% CI),  
per 100 person-years 
Incidence Rate 
Ratio (95% CI) 
P 
value 
HCV primary and re-infection           
Total participants           
   2014-17 807 67 8.31 (6.54, 10.55) 1.00   
   2018-19 1,011 44 4.35 (3.24, 5.85) 0.52 (0.36, 0.78) <0.01 
Participants never injected           
   2014-17 458 7 1.53 (0.73, 3.20) 1.00   
   2018-19 541 7 1.29 (0.62, 2.72) 0.84 (0.30, 2.42) 0.76 
Participants with a history of injecting, but not in current 
imprisonment 
          
   2014-17 126 13 10.30 (5.98, 17.73) 1.00   
   2018-19 171 7 4.10 (1.95, 8.60) 0.40 (0.16, 0.98) 0.04 
Participants who injected in current imprisonment           
   2014-17 216 47 21.74 (16.34, 28.94) 1.00   
   2018-19 293 30 10.25 (7.17, 14.67) 0.47 (0.30, 0.75) <0.01 
HCV primary infection           
Total participants           
   2014-17 572 38 6.64 (4.83, 9.13) 1.00   
   2018-19 667 19 2.85 (1.82, 4.46) 0.43 (0.25, 0.74) <0.01 
Participants never injected           
   2014-17 447 5 1.12 (0.47, 2.69) 1.00   
   2018-19 524 7 1.34 (0.64, 2.80) 1.19 (0.38, 3.76) 0.76 
Participants with a history of injecting, but not in current 
imprisonment 
          
   2014-17 61 10 16.34 (8.79, 30.38) 1.00   
   2018-19 80 4 5.00 (1.88, 13.32) 0.31 (0.10, 0.98) 0.03 
Participants who injected in current imprisonment           
   2014-17 59 23 39.08 (25.97, 58.82) 1.00   
   2018-19 57 8 14.03 (7.02, 28.5) 0.36 (0.16, 0.80) <0.01 
HCV re-infection           
Total participants           
   2014-17 235 29 12.36 (8.59, 17.79) 1.00   
   2018-19 344 25 7.27 (4.92, 10.76) 0.59 (0.35, 1.00) 0.05 
Participants never injected           
   2014-17 12 2 17.02 (4.26, 68.07)     
   2018-19 17 0 0.00 (0.00, 17.65)*  -  - 
Participants with a history of injecting, but not in current 
imprisonment 
          
   2014-17 65 3 4.61 (1.49, 14.30) 1.00   
   2018-19 91 3 3.31 (1.07, 10.25) 0.72 (0.15, 3.55) 0.68 
Participants who injected in current imprisonment           
   2014-17 157 24 15.26 (10.23, 22.76) 1.00   
   2018-19 236 22 9.34 (6.15, 14.19) 0.61 (0.34, 1.09) 0.09 




Table 3: Unadjusted and adjusted Cox Proportional Hazards models evaluating the factors associated 
with the risk of HCV infection 
  
Unadjusted Hazard 




Ratio (95% CI)* 
P 
value 
Study period         
   2014-17 1.00   1.00   
   2018-19 0.55 (0.37, 0.82) <0.01 0.50 (0.33, 0.76) <0.01 
Gender†         
  Female 1.00       
  Male 0.62 (0.39, 0.98) 0.04     
Age at enrolment (year) 0.92 (0.89, 0.94) <0.01 0.92 (0.89, 0.95) <0.01 
Age at enrolment (year)         
  25 years or younger 1.00       
  25-35 years 0.67 (0.44, 1.01) 0.06     
  35-45 years 0.30 (0.17, 0.53) <0.01     
  Older than 45 years 0.04 (0.01, 0.18)  <0.01     
Aboriginal and or Torres Strait Islander         
  No 1.00   1.00   
  Yes 2.01 (1.37, 2.96) <0.01 1.02 (0.66, 1.57) 0.93 
Duration of stay in current prison at enrolment         
  Up to 12 months 1.00   1.00   
  13-24 months 0.69 (0.40, 1.18) 0.17 0.92 (0.51, 1.67) 0.79 
  25-36 months 0.54 (0.28, 1.03) 0.06 0.89 (0.44, 1.82) 0.76 
  >36 months 0.39 (0.25, 0.63) <0.01 0.82 (0.46, 1.44) 0.48 
Previous imprisonment         
  No 1.00   1.00   
  Yes 3.02 (1.78, 5.14) <0.01 2.27 (1.21, 4.26) 0.01 
Injecting drug use status         
  Not injected in current imprisonment 1.00   1.00   
  Injected longer than 6 months ago (current imprisonment) 4.52 (1.61, 12.73) <0.01 3.32 (1.04, 10.59) 0.04 
  Injected in the previous 6 months (current imprisonment) 10.32 (5.27, 20.20) <0.01 6.14 (3.16, 11.92) <0.01 
Prison site at the last visit†         
  Lithgow 1.00   1.00    
  Dillwynia 2.05 (1.16, 3.62) 0.01 2.10 (1.06, 4.15) 0.03 
  Goulburn 2.02 (1.26, 3.25) <0.01 1.97 (1.18, 3.29) <0.01 
  OMMPCC 0.53 (0.25, 1.14) 0.10 1.18 (0.53, 2.63) 0.69 
* 1,785 person-year follow-up with 110 incident events included in the model 








Figure 1: Overview of SToP-C study participants 
* HCV test results at enrolment were not available for 7 participants. 
† Most (n=96) are participants who were enrolled during late 2019 and were not due for follow-up or there was no 
access to the participant by the end of the study. 
‡ For participants receiving treatment through SToP-C, ETR was considered given that phylogenetic analysis was 
used to distinguish post-treatment re-infection from relapse. For other participants SVR was considered. 














Figure 2: HCV status at enrolment by year of enrolment among total SToP-C participants (A), among total 







Figure 3: Number of participants receiving HCV treatment through the SToP-C study or outside of the 











Figure 4: Biannual incidence of all HCV infection (A), primary HCV infection (B), and HCV re-infection 
(C) in the SToP-C study  










Figure 5: The trend of incidence of all HCV infection (A), primary HCV infection (B), and HCV re-infection 
(C) in the SToP-C study 
Red solid line represents the observed trend and red dashed line represents predicted counterfactual by removing 
the effect of the intervention for after 2017 
